OBJECTIVE: To examine the feasibility of continuous glucose monitoring (CGM) use in very young children with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Twenty-three children less than 4 yr of age with T1D were provided with a FreeStyle Navigator(®) (n = 21) or a Paradigm(®) (n = 2) CGM device. At baseline, mean age was 3.0 ± 0.8 yr, mean hemoglobin A1c (HbA1c) was 8.0 ± 0.8%, 10 were using an insulin pump and 13 were on multiple daily injections. CGM use was evaluated over a 6-month period. RESULTS: Three children dropped out of the study before the end of 6 months. Among the 20 children who completed 6 months of follow-up, CGM use in month 6 was ≥6 d/wk in 9 (45%), 4 ≤ 6 d/wk in 2 (10%), and <4 d/wk in 9 (45%). Skin reactions were minimal. Although there was no detectable change in mean HbA1c between baseline and 6 months (7.9 and 8.0%, respectively), there was a high degree of parental satisfaction with CGM as measured on the CGM satisfaction scale questionnaire. A high percentage of glucose values were in the hyperglycemic range, and biochemical hypoglycemia was infrequent. CONCLUSION: More than 40% of very young children were able to safely use CGM on a near-daily basis after 6 months. CGM demonstrated frequent hyperglycemic excursions, with a large variability in glucose readings. Although improvement in glycemic control was not detected in the group as a whole, parental satisfaction with CGM was high.
OBJECTIVE: To examine the feasibility of continuous glucose monitoring (CGM) use in very young children with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Twenty-three children less than 4 yr of age with T1D were provided with a FreeStyle Navigator(®) (n = 21) or a Paradigm(®) (n = 2) CGM device. At baseline, mean age was 3.0 ± 0.8 yr, mean hemoglobin A1c (HbA1c) was 8.0 ± 0.8%, 10 were using an insulin pump and 13 were on multiple daily injections. CGM use was evaluated over a 6-month period. RESULTS: Three children dropped out of the study before the end of 6 months. Among the 20 children who completed 6 months of follow-up, CGM use in month 6 was ≥6 d/wk in 9 (45%), 4 ≤ 6 d/wk in 2 (10%), and <4 d/wk in 9 (45%). Skin reactions were minimal. Although there was no detectable change in mean HbA1c between baseline and 6 months (7.9 and 8.0%, respectively), there was a high degree of parental satisfaction with CGM as measured on the CGM satisfaction scale questionnaire. A high percentage of glucose values were in the hyperglycemic range, and biochemical hypoglycemia was infrequent. CONCLUSION: More than 40% of very young children were able to safely use CGM on a near-daily basis after 6 months. CGM demonstrated frequent hyperglycemic excursions, with a large variability in glucose readings. Although improvement in glycemic control was not detected in the group as a whole, parental satisfaction with CGM was high.
Authors: Stuart A Weinzimer; JoAnn H Ahern; Elizabeth A Doyle; Miranda R Vincent; James Dziura; Amy T Steffen; William V Tamborlane Journal: Pediatrics Date: 2004-12 Impact factor: 7.124
Authors: Linda A DiMeglio; Tina M Pottorff; Sheryl R Boyd; Lisa France; Naomi Fineberg; Erica A Eugster Journal: J Pediatr Date: 2004-09 Impact factor: 4.406
Authors: M A Van Name; K M Miller; P V Commissariat; A L Whitehouse; K R Harrington; B J Anderson; M G Mantravadi; W Levy; D J DeSalvo; W V Tamborlane; M E Hilliard; L M Laffel; L A DiMeglio Journal: Diabet Med Date: 2019-07-25 Impact factor: 4.359
Authors: M Tansey; R Beck; K Ruedy; W Tamborlane; P Cheng; C Kollman; L Fox; S Weinzimer; N Mauras; N H White; E Tsalikian Journal: Pediatr Diabetes Date: 2014-12-11 Impact factor: 4.866